The Hepatitis C Virus (HCV) NS4B RNA Binding Inhibitor Clemizole Is Highly Synergistic with HCV Protease Inhibitors | Zendy

Shirit Einav | Zendy; Hadas D. Sobol | Zendy; Elizabeth Gehrig | Zendy; Jeffrey S. Glenn | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Hepatitis C Virus (HCV) NS4B RNA Binding Inhibitor Clemizole Is Highly Synergistic with HCV Protease Inhibitors

Author(s) -

Shirit Einav,

Hadas D. Sobol,

Elizabeth Gehrig,

Jeffrey S. Glenn

Publication year - 2010

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/653080

Subject(s) - virology , hepatitis c virus , ribavirin , protease inhibitor (pharmacology) , protease , biology , ns5b , ns3 , viral replication , virus , drug resistance , hepacivirus , pharmacology , viral load , enzyme , microbiology and biotechnology , biochemistry , antiretroviral therapy

We recently identified a compound, clemizole hydrochloride, that inhibits NS4B's RNA binding and hepatitis C virus (HCV) replication. Although significant, clemizole's antiviral effect is moderate (50% effective concentration of 8 microM against an HCV genotype 2a clone). We hypothesized that the combination of clemizole with other anti-HCV agents can increase the antiviral effect over that achieved with each drug alone and could also decrease the emergence of viral resistance.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research